ADVFN US – Market Content Editor
-
Xtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beat
Xtant Medical Holdings (AMEX:XTNT) shares fell about 4.7% in pre-market trading Tuesday after the company reported fourth-quarter results that topped expectations but issued 2026 revenue guidance well below Wall Street forecasts. For the quarter, the medical technology firm posted adjusted earnings per share of $0.00, outperforming the analyst estimate of -$0.01. Revenue came in at…
-
Weight Watchers introduces discounted Wegovy pricing through Novo Nordisk partnership
WW International Inc. (NASDAQ:WW) said its Med+ members will gain access to reduced pricing for Wegovy through an expanded collaboration with Novo Nordisk (NYSE:NVO), lowering out-of-pocket costs for patients paying without insurance. The program gives Weight Watchers Med+ members access to subscription-based pricing for Wegovy doses, potentially delivering savings of up to $1,200 per year…
-
Nebius shares rise after unveiling plans for major AI facility in Finland
Nebius Group (NASDAQ:NBIS) shares climbed about 3.5% on Tuesday after the company revealed plans to construct a 310 MW AI factory in Lappeenranta, Finland, with initial capacity expected to come online in 2027. Once fully built, the facility is expected to rank among Europe’s largest dedicated AI infrastructure hubs and forms part of Nebius’s broader…
-
Aehr Test shares jump 13% after securing silicon photonics system order
Shares of Aehr Test Systems (NASDAQ:AEHR) climbed 13% after the company revealed it had received an initial order from a new customer described as a global leader in networking equipment and a key supplier to the data center optical transceiver market. The order covers several systems intended for both engineering qualification and high-volume production. These…
-
Novo Nordisk introduces discounted Wegovy subscription plan in the U.S.
Novo Nordisk (NYSE:NVO) has rolled out a new subscription-based pricing program in the United States aimed at patients paying out of pocket for Wegovy without insurance coverage. The initiative provides monthly discounts of up to 29% through several telehealth providers. Beginning Tuesday, eligible self-pay patients can obtain three-, six-, or 12-month supplies of Wegovy at…
-
Hershey presents snacking growth roadmap at investor day, confirms 2026 outlook
The Hershey Company (NYSE:HSY) hosted its 2026 Investor Day at the New York Stock Exchange, where leadership detailed the company’s strategy to drive long-term expansion in the global snacking sector. Chief Executive Officer Kirk Tanner highlighted Hershey’s plan to broaden its portfolio beyond traditional confectionery products by strengthening its presence in premium, better-for-you offerings while…
-
Delta selects Amazon’s LEO network for in-flight Wi-Fi, dealing blow to Starlink
Delta Air Lines Inc. (NYSE:DAL) has reached an agreement with Amazon.com Inc. (NASDAQ:AMZN) to use the company’s low-Earth orbit satellite service for onboard Wi-Fi, handing Amazon’s space venture a notable aviation customer as it competes with SpaceX’s Starlink. Delta said Tuesday the connectivity system will be installed on 500 aircraft starting in 2028, initially focusing…
-
Centessa shares soar after Lilly announces multibillion-dollar acquisition deal
Centessa Pharmaceuticals (NASDAQ:CNTA) shares surged more than 46% in pre-market trading Tuesday after Eli Lilly (NYSE:LLY) revealed a definitive agreement to acquire the clinical-stage biotech company in a transaction valued at up to $7.8 billion, including contingent milestone payments. Under the terms of the deal, Lilly will pay $38 per share in cash, representing an…
-
FactSet shares jump nearly 7% after earnings beat
FactSet Research Systems Inc. (NYSE:FDS) reported second-quarter results on Tuesday that topped analyst forecasts, sending the financial data provider’s shares sharply higher in early trading. The stock rose about 6.7% in pre-market trading after the company posted stronger growth across several segments of its business. FactSet reported adjusted earnings per share of $4.46 for the…
-
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss
Jasper Therapeutics Inc. (NASDAQ:JSPR) reported a fourth-quarter loss of $0.32 per share for the period ending December 31, 2025. The company currently generates no revenue, as it remains focused on clinical development of its lead drug candidate, briquilimab. Despite the loss, the biotechnology company’s shares climbed 5.44% in pre-market trading following the announcement, as investors…